Medifoxamine: oral tolerance and pharmacokinetic study in healthy human volunteers.
Medifoxamine is a monoamine reuptake inhibiting antidepressant drug. We have investigated its pharmacokinetics in normal healthy volunteers. After an overnight fast, ascending doses of 200, 500, 750 and 1000 mg of medifoxamine were taken orally. Plasma samples were analysed using a specific HPLC method. Medifoxamine was well tolerated and exhibited a first order linear pharmacokinetic profile. It underwent rapid absorption and peak plasma concentrations were achieved about 1.0 h after administration. Thereafter the elimination profile was biphasic with a mean terminal half life less than 3 hours. We found a linear relationship (r = 0.80) between administered dose and AUC values for the four doses. High values were obtained for the apparent volumes of distribution and the plasma clearance.
Saleh
S
S
Clinical Pharmacology, St. Bartholomew's Hospital, London, UK.
Johnston
A
A
Turner
P
P
D000284:Administration, Oral; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D004361:Drug Tolerance; D005021:Ethylamines / Q000009:adverse effects / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D015644:Miocamycin / Q000494:pharmacology*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics*
D005021:Ethylamines; D008996:Monoamine Oxidase Inhibitors; D015644:Miocamycin; C034065:medifoxamine